Gilead Sciences (GILD) Stock Price & Analysis

GILD$168.08+0.13 +0.08%
Drug Manufacturers - GeneralMega Cap
Compare
Market cap$208.48BEnterprise value$236.14BRevenue (TTM)$30.99BMarket positionTop 5%

Score

37
Bearish
Value
30
Quality
44
Growth
38

AI Analysis

Snapshot

Gilead Sciences doesn’t screen as a clean setup today — Stocklytics 37/100 leaves more to prove. Under the hood: 1.9% dividend yield.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

30
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

38
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

44
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Gilead Sciences, Inc. (GILD) last printed $168.08. Equity value is $208.48B. Trailing earnings multiple —. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$30.39B$26.11B$22.13B$22.45B$24.69B$27.3B$27.28B$27.12B$28.75B$29.44B

About

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

Gilead Sciences (GILD) Stock Price & Analysis

GILD price $168.08 +0.13 +0.08%

Ticker
GILD
Price
$168.08
Change
+0.13 +0.08%
Market cap
$208.48B
Forward P/E
19.65
Dividend yield
1.86%
Beta
0.36
Sector
Healthcare
Industry
Drug Manufacturers - General
Stocklytics score
37
Value
30
Quality
44
Growth
38

Stocklytics score rationale: value 30, quality 44, growth 38.

AI Score 45. Gilead Sciences, Inc. has a market cap of $211.6 billion but is facing significant profitability challenges, with a net profit margin of -0.1247 and a price-to-earnings ratio of -55.1

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener